Insulino‐mimetic and anti‐diabetic effects of vanadium compounds
暂无分享,去创建一个
[1] J. Domingo. Vanadium and tungsten derivatives as antidiabetic agents , 2002, Biological Trace Element Research.
[2] S. Pugazhenthi,et al. Does the insulin-mimetic action of vanadate involve insulin receptor kinase? , 1993, Molecular and Cellular Biochemistry.
[3] S. Semiz,et al. Oral treatment with vanadium of Zucker fatty rats activates muscle glycogen synthesis and insulin-stimulated protein phosphatase-1 activity , 2002, Molecular and Cellular Biochemistry.
[4] J. McNeill,et al. Vanadium increases GLUT4 in diabetic rat skeletal muscle , 2002, Molecular and Cellular Biochemistry.
[5] S. Semiz,et al. Effects of diabetes, vanadium, and insulin on glycogen synthase activation in Wistar rats , 2002, Molecular and Cellular Biochemistry.
[6] S. Bhanot,et al. In vivo effects of insulin and bis(maltolato)oxovanadium (IV) on PKB activity in the skeletal muscle and liver of diabetic rats , 2001, Molecular and Cellular Biochemistry.
[7] S. Bhanot,et al. In vivo effects of vanadium in diabetic rats are independent of changes in PI‐3 kinase activity in skeletal muscle , 2001, Molecular and Cellular Biochemistry.
[8] A. Lochner,et al. Effect of Vanadate and Insulin on Glucose Transport in Isolated Adult Rat Cardiomyocytes , 2000, Cardiovascular Drugs and Therapy.
[9] A. Srivastava. Anti-diabetic and toxic effects of vanadium compounds , 2000, Molecular and Cellular Biochemistry.
[10] J. McNeill,et al. Vanadium and diabetes , 1998, Molecular and Cellular Biochemistry.
[11] S. Pandey,et al. Potential mechanism(s) involved in the regulation of glycogen synthesis by insulin , 1998, Molecular and Cellular Biochemistry.
[12] M. White,et al. The IRS-signalling system: A network of docking proteins that mediate insulin action , 1998, Molecular and Cellular Biochemistry.
[13] J. Domingo,et al. Toxicology of vanadium compounds in diabetic rats: The action of chelating agents on vanadium accumulation , 1995, Molecular and Cellular Biochemistry.
[14] C. Kahn,et al. In vivo andin vitro studies of vanadate in human and rodent diabetes mellitus , 1995, Molecular and Cellular Biochemistry.
[15] Han‐Chung Wang,et al. Unique and selective mitogenic effects of vanadate on SV40-transformed cells , 1995, Molecular and Cellular Biochemistry.
[16] S. Pugazhenthi,et al. Decrease in protein tyrosine phosphatase activities in vanadate-treated obese Zucker (fa/fa) rat liver , 1995, Molecular and Cellular Biochemistry.
[17] S. Pugazhenthi,et al. In vivo effects of vanadate on hepatic glycogen metabolizing and lipogenic enzymes in insulin-dependent and insulin-resistant diabetic animals , 1995, Molecular and Cellular Biochemistry.
[18] S. Pugazhenthi,et al. Effects of high sucrose diet on insulin-like effects of vanadate in diabetic rats , 1993, Molecular and Cellular Biochemistry.
[19] S. Pugazhenthi,et al. Effects of vanadate administration on the high sucrose diet-induced aberrations in normal rats , 1993, Molecular and Cellular Biochemistry.
[20] R. Sargeant,et al. Vanadate induces the recruitment of glut-4 glucose transporter to the plasma membrane of rat adipocytes , 1992, Molecular and Cellular Biochemistry.
[21] O. Blondel,et al. In vivo insulin resistance in streptozotocin-diabetic rats — evidence for reversal following oral vanadate treatment , 1989, Diabetologia.
[22] J. McNeill,et al. In vivo effects of vanadium on GLUT4 translocation in cardiac tissue of STZ-diabetic rats , 2004, Molecular and Cellular Biochemistry.
[23] J. McNeill,et al. Bis(maltolato)oxovanadium(IV) inhibits the activity of PTP1B in Zucker rat skeletal muscle in vivo , 2004, Molecular and Cellular Biochemistry.
[24] I. G. Fantus,et al. Multifunctional actions of vanadium compounds on insulin signaling pathways: Evidence for preferential enhancement of metabolic versus mitogenic effects , 1998, Molecular and Cellular Biochemistry.
[25] S. Brichard. Outlook of diabetes treatment possibilities with vanadium and other metal salts , 2003 .
[26] J. McNeill,et al. Mechanisms by which bis(maltolato)oxovanadium(IV) normalizes phosphoenolpyruvate carboxykinase and glucose-6-phosphatase expression in streptozotocin-diabetic rats in vivo. , 2002, Endocrinology.
[27] M. White,et al. IRS proteins and the common path to diabetes. , 2002, American journal of physiology. Endocrinology and metabolism.
[28] J. Waring,et al. PTP1B antisense oligonucleotide lowers PTP1B protein, normalizes blood glucose, and improves insulin sensitivity in diabetic mice , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[29] B. Goldstein. Protein-tyrosine phosphatases: emerging targets for therapeutic intervention in type 2 diabetes and related states of insulin resistance. , 2002, The Journal of clinical endocrinology and metabolism.
[30] A. Kiersztan,et al. Inhibition of gluconeogenesis by vanadium and metformin in kidney-cortex tubules isolated from control and diabetic rabbits. , 2002, Biochemical pharmacology.
[31] B. Monia,et al. Specific inhibition of PTEN expression reverses hyperglycemia in diabetic mice. , 2002, Diabetes.
[32] J. Molero,et al. Activation of MAP kinase by insulin and vanadate in adipocytes from young and old rats , 2002, Molecular and Cellular Endocrinology.
[33] K. Goa,et al. Rosiglitazone , 2012, Drugs.
[34] José L Domingo,et al. Vanadium and tungsten derivatives as antidiabetic agents: a review of their toxic effects. , 2002, Biological trace element research.
[35] D. Accili,et al. The forkhead transcription factor Foxo1 (Fkhr) confers insulin sensitivity onto glucose-6-phosphatase expression. , 2001, The Journal of clinical investigation.
[36] J. McNeill,et al. Effect of vanadium on insulin sensitivity and appetite. , 2001, Metabolism: clinical and experimental.
[37] P. Lochhead,et al. Inhibition of GSK-3 Selectively Reduces Glucose-6-Phosphatase and Phosphoenolpyruvate Carboxykinase Gene Expression , 2001 .
[38] É. Hajduch,et al. Protein kinase B (PKB/Akt) – a key regulator of glucose transport? , 2001, FEBS letters.
[39] R. DeFronzo,et al. The Journal of Clinical Endocrinology & Metabolism Printed in U.S.A. Copyright © 2001 by The Endocrine Society COMMENT Vanadyl Sulfate Improves Hepatic and Muscle Insulin Sensitivity in Type 2 Diabetes* , 2022 .
[40] J. Hardman,et al. Insulin, oral hypoglycemic agents and the pharmacology of the endocrine pancreas , 2001 .
[41] M. Khamaisi,et al. Treatment of diabetes with vanadium salts: general overview and amelioration of nutritionally induced diabetes in the Psammomys obesus gerbil , 2001, Diabetes/metabolism research and reviews.
[42] J. McNeill,et al. Mechanisms of vanadium action: insulin-mimetic or insulin-enhancing agent? , 2000, Canadian journal of physiology and pharmacology.
[43] Y. Shechter,et al. Organic vanadium chelators potentiate vanadium-evoked glucose metabolism in vitro and in vivo: establishing criteria for optimal chelators. , 2000, Molecular pharmacology.
[44] J. Olefsky. Treatment of insulin resistance with peroxisome proliferator–activated receptor γ agonists , 2000 .
[45] H. Sakurai,et al. Evidence for the Improvement of Noninsulin‐Dependent Diabetes Mellitus in KKAy Mice with Daily Oral Administration of Bis(6‐methylpicolinato)oxovanadium(IV) Complex. , 2000 .
[46] M. Shefi,et al. Gluconeogenesis in non-obese diabetic (NOD) mice: in vivo effects of vandadate treatment on hepatic glucose-6-phoshatase and phosphoenolpyruvate carboxykinase. , 2000, Metabolism: clinical and experimental.
[47] C. Kahn,et al. Metabolic effects of vanadyl sulfate in humans with non-insulin-dependent diabetes mellitus: in vivo and in vitro studies. , 2000, Metabolism: clinical and experimental.
[48] J. Olefsky. Treatment of insulin resistance with peroxisome proliferator-activated receptor gamma agonists. , 2000, The Journal of clinical investigation.
[49] A. Tracey,et al. Bis(N,N-dimethylhydroxamido)hydroxooxovanadate inhibition of protein tyrosine phosphatase activity in intact cells: comparison with vanadate. , 1999, Biochemical pharmacology.
[50] H. Sakurai,et al. Evidence for the improvement of noninsulin-dependent diabetes mellitus in KKAy mice with daily oral administration of bis(6-methylpicolinato)oxovanadium(IV) complex. , 1999, Chemical & pharmaceutical bulletin.
[51] M. Bernier,et al. Phosphatidylinositol 3-kinase requirement in activation of the ras/C-raf-1/MEK/ERK and p70(s6k) signaling cascade by the insulinomimetic agent vanadyl sulfate. , 1999, Biochemistry.
[52] P. Cohen,et al. Phosphorylation of the Transcription Factor Forkhead Family Member FKHR by Protein Kinase B* , 1999, The Journal of Biological Chemistry.
[53] D. Accili,et al. Insulin Stimulates Phosphorylation of the Forkhead Transcription Factor FKHR on Serine 253 through a Wortmannin-sensitive Pathway* , 1999, The Journal of Biological Chemistry.
[54] Feng Liu,et al. Primary Structure, Tissue Distribution, and Expression of Mouse Phosphoinositide-dependent Protein Kinase-1, a Protein Kinase That Phosphorylates and Activates Protein Kinase Cζ* , 1999, The Journal of Biological Chemistry.
[55] Independent signal-transduction pathways for vanadate and for insulin in the activation of glycogen synthase and glycogenesis in rat adipocytes. , 1999, Endocrinology.
[56] S. Brichard,et al. Effects of vanadium complexes with organic ligands on glucose metabolism: a comparison study in diabetic rats , 1999, British journal of pharmacology.
[57] M. Battell,et al. Acute and chronic oral administration of bis(maltolato)oxovanadium(IV) in Zucker diabetic fatty (ZDF) rats. , 1999, Diabetes research and clinical practice.
[58] I. G. Fantus,et al. Tyrosine phosphatase inhibitors, vanadate and pervanadate, stimulate glucose transport and GLUT translocation in muscle cells by a mechanism independent of phosphatidylinositol 3-kinase and protein kinase C. , 1998, Diabetes.
[59] H. King,et al. Global Burden of Diabetes, 1995–2025: Prevalence, numerical estimates, and projections , 1998, Diabetes Care.
[60] A. Evangelou,et al. Beneficial effects of a vanadium complex with cysteine, administered at low doses on benzo(alpha)pyrene-induced leiomyosarcomas in Wistar rats. , 1998, Anticancer research.
[61] K. Siddle,et al. Phosphoinositide 3-kinase: the key switch mechanism in insulin signalling. , 1998, The Biochemical journal.
[62] Tomohiko Maehama,et al. The Tumor Suppressor, PTEN/MMAC1, Dephosphorylates the Lipid Second Messenger, Phosphatidylinositol 3,4,5-Trisphosphate* , 1998, The Journal of Biological Chemistry.
[63] Vanadyl sulfate-stimulated glycogen synthesis is associated with activation of phosphatidylinositol 3-kinase and is independent of insulin receptor tyrosine phosphorylation. , 1998, Biochemistry.
[64] Y. Shechter,et al. Vanadate elevates lipogenicity of starved rat adipose tissue: mechanism of action. , 1998, Endocrinology.
[65] J. Downward. Mechanisms and consequences of activation of protein kinase B/Akt. , 1998, Current opinion in cell biology.
[66] B. Spiegelman. PPAR-gamma: adipogenic regulator and thiazolidinedione receptor. , 1998, Diabetes.
[67] J. Molero,et al. Vanadate fully stimulates insulin receptor substrate‐1 associated phosphatidyl inositol 3‐kinase activity in adipocytes from young and old rats , 1998, FEBS letters.
[68] J. Domingo,et al. Effects of Vanadium on Activity and Learning in Rats , 1998, Physiology & Behavior.
[69] E. Ziv,et al. Cellular Mechanism of Nutritionally Induced Insulin Resistance: The Desert Rodent Psammomys obesus and Other Animals in which Insulin Resistance leads to Detrimental Outcome , 1998, Journal of basic and clinical physiology and pharmacology.
[70] G. Elberg,et al. Vanadate Activates Membranous Nonreceptor Protein Tyrosine Kinase in Rat Adipocytes , 1997, Diabetes.
[71] G. Dohm,et al. Vanadate stimulation of 2-deoxyglucose transport is not mediated by PI 3-kinase in human skeletal muscle. , 1997, Biochimica et biophysica acta.
[72] F. Romano,et al. Effects of oral vanadyl treatment on diabetes-induced alterations in the heart GLUT-4 transporter. , 1997, Journal of molecular and cellular cardiology.
[73] I. G. Fantus,et al. Vanadium Compounds Biological Actions and Potential as Pharmacological Agents , 1997, Trends in Endocrinology & Metabolism.
[75] S. Pugazhenthi,et al. Inhibition of a Src homology 2 domain containing protein tyrosine phosphatase by vanadate in the primary culture of hepatocytes. , 1996, Archives of biochemistry and biophysics.
[76] W. Waldhäusl,et al. Insulin-like vs. non-insulin-like stimulation of glucose metabolism by vanadium, tungsten, and selenium compounds in rat muscle. , 1996, Life sciences.
[77] G. Boden,et al. Effects of vanadyl sulfate on carbohydrate and lipid metabolism in patients with non-insulin-dependent diabetes mellitus. , 1996, Metabolism: clinical and experimental.
[78] R. Pederson,et al. Effects of low and high dose administration of bis(maltolato)oxovanadium(IV) on fa/fa Zucker rats. , 1996, Canadian journal of physiology and pharmacology.
[79] P. Cohen,et al. Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B , 1995, Nature.
[80] B. Posner,et al. Arrest at the G2/M transition of the cell cycle by protein‐tyrosine phosphatase inhibition: Studies on a neuronal and a glial cell line , 1995, Journal of cellular biochemistry.
[81] C. Kahn,et al. Metabolic effects of sodium metavanadate in humans with insulin-dependent and noninsulin-dependent diabetes mellitus in vivo and in vitro studies. , 1995, The Journal of clinical endocrinology and metabolism.
[82] B. Posner,et al. Hypoglycemic Effects of Peroxovanadium Compounds in Sprague-Dawley and Diabetic BB Rats , 1995, Diabetes.
[83] A. Srivastava. Section Review—Oncologic, Endocrine & Metabolic: Potential Use of Vanadium Compounds in the Treatment of Diabetes Mellitus , 1995 .
[84] G. Dohm,et al. Okadaic Acid, Vanadate, and Phenylarsine Oxide Stimulate 2-Deoxyglucose Transport in Insulin-Resistant Human Skeletal Muscle , 1995, Diabetes.
[85] H. Shamoon,et al. Oral vanadyl sulfate improves hepatic and peripheral insulin sensitivity in patients with non-insulin-dependent diabetes mellitus. , 1995, The Journal of clinical investigation.
[86] C. Djordjevic. Antitumor activity of vanadium compounds. , 1995, Metal ions in biological systems.
[87] J. Berger,et al. PI 3-kinase activation is required for insulin stimulation of glucose transport into L6 myotubes. , 1994, Biochemical and biophysical research communications.
[88] B. Harland,et al. Is vanadium of human nutritional importance yet? , 1994, Journal of the American Dietetic Association.
[89] J. Henquin,et al. Comparison of the effects of various vanadium salts on glucose homeostasis in streptozotocin-diabetic rats. , 1994, European journal of pharmacology.
[90] A. Srivastava,et al. Activation of mitogen activated protein (MAP) kinases by vanadate is independent of insulin receptor autophosphorylation , 1994, FEBS letters.
[91] I. G. Fantus,et al. Peroxovanadium compounds. A new class of potent phosphotyrosine phosphatase inhibitors which are insulin mimetics. , 1994, The Journal of biological chemistry.
[92] C. Kahn,et al. The insulin signaling system. , 1994, The Journal of biological chemistry.
[93] H. McCarthy,et al. Effects of Chronic Vanadate Administration in the STZ-Induced Diabetic Rat: The Antihyperglycemic Action of Vanadate Is Attributable Entirely to Its Suppression of Feeding , 1994, Diabetes.
[94] A. Shisheva,et al. The protein tyrosine phosphatase inhibitor, pervanadate, is a powerful antidiabetic agent in streptozotocin-treated diabetic rats. , 1994, Endocrinology.
[95] F. Bosch,et al. Vanadate treatment restores the expression of genes for key enzymes in the glucose and ketone bodies metabolism in the liver of diabetic rats. , 1993, The Journal of clinical investigation.
[96] A. Shisheva,et al. Role of cytosolic tyrosine kinase in mediating insulin-like actions of vanadate in rat adipocytes. , 1993, The Journal of biological chemistry.
[97] J. McNeill,et al. Glucose-lowering effects of a new organic vanadium complex, bis(maltolato)oxovanadium(IV). , 1993, Canadian journal of physiology and pharmacology.
[98] J. McNeill,et al. Improvement in cardiac dysfunction in streptozotocin-induced diabetic rats following chronic oral administration of bis(maltolato)oxovanadium(IV). , 1993, Canadian journal of physiology and pharmacology.
[99] J. Girard,et al. Vanadate treatment of diabetic rats reverses the impaired expression of genes involved in hepatic glucose metabolism: Effects on glycolytic and gluconeogenic enzymes, and on glucose transporter GLUT2 , 1993, Molecular and Cellular Endocrinology.
[100] P. J. Jones,et al. Role of vanadium in nutrition: metabolism, essentiality and dietary considerations. , 1993, Life sciences.
[101] C. Kahn,et al. Insulin differentially regulates protein phosphotyrosine phosphatase activity in rat hepatoma cells. , 1992, Biochemistry.
[102] J. Tavaré,et al. Characterization of insulin-stimulated protein serine/threonine kinases in CHO cells expressing human insulin receptors with point and deletion mutations. , 1992, The Biochemical journal.
[103] A. Shisheva,et al. Quercetin selectively inhibits insulin receptor function in vitro and the bioresponses of insulin and insulinomimetic agents in rat adipocytes. , 1992, Biochemistry.
[104] S. Brichard,et al. Vanadate treatment markedly increases glucose utilization in muscle of insulin-resistant fa/fa rats without modifying glucose transporter expression. , 1992, Endocrinology.
[105] C. Bailey. Biguanides and NIDDM , 1992, Diabetes Care.
[106] L. Groop. Sulfonylureas in NIDDM , 1992, Diabetes Care.
[107] J. McNeill,et al. Bis(maltolato)oxovanadium(IV) is a potent insulin mimic. , 1992, Journal of medicinal chemistry.
[108] F. Bosch,et al. Activation by Vanadate of Glycolysis in Hepatocytes From Diabetic Rats , 1991, Diabetes.
[109] S. Pugazhenthi,et al. Long-term effects of vanadate treatment on glycogen metabolizing and lipogenic enzymes of liver in genetically diabetic (db/db) mice. , 1991, Metabolism: clinical and experimental.
[110] Y. Shechter,et al. Vanadate inhibits glucose output from isolated perfused rat liver , 1991, Hepatology.
[111] S. Pugazhenthi,et al. Insulin-like effect of vanadate on malic enzyme and glucose-6-phosphate dehydrogenase activities in streptozotocin-induced diabetic rat liver. , 1991, Biochimica et biophysica acta.
[112] H. Lodish,et al. Decreased in vivo glucose uptake but normal expression of GLUT1 and GLUT4 in skeletal muscle of diabetic rats. , 1991, The Journal of clinical investigation.
[113] M. Davidson,et al. Antidiabetic Action of Vanadyl in Rats Independent of in Vivo Insulin-Receptor Kinase Activity , 1991, Diabetes.
[114] C. Kahn,et al. Vanadate normalizes hyperglycemia in two mouse models of non-insulin-dependent diabetes mellitus. , 1991, The Journal of clinical investigation.
[115] S. Brichard,et al. Marked Improvement of Glucose Homeostasis in Diabetic ob/ob Mice Given Oral Vanadate , 1990, Diabetes.
[116] J. McNeill,et al. Toxicological aspects of vanadyl sulphate on diabetic rats: effects on vanadium levels and pancreatic B-cell morphology. , 1990, Pharmacology & toxicology.
[117] M. Permutt,et al. Effects of altered glucose homeostasis on glucose transporter expression in skeletal muscle of the rat. , 1990, The Journal of clinical investigation.
[118] W. M. Sherman,et al. Exercise training increases glucose transporter protein GLUT‐4 in skeletal muscle of obese Zucker (fa/fa) rats , 1990, FEBS letters.
[119] S. Pugazhenthi,et al. Insulinlike Effects of Vanadate on Hepatic Glycogen Metabolism in Nondiabetic and Streptozocin-Induced Diabetic Rats , 1990, Diabetes.
[120] J. Berger,et al. Vanadate treatment of streptozotocin diabetic rats restores expression of the insulin-responsive glucose transporter in skeletal muscle. , 1990, Endocrinology.
[121] J. McNeill,et al. Enhanced in vivo sensitivity of vanadyl-treated diabetic rats to insulin. , 1990, Canadian journal of physiology and pharmacology.
[122] J. Simon,et al. Impaired insulin action but normal insulin receptor activity in diabetic rat liver: effect of vanadate. , 1990, The American journal of physiology.
[123] M. Permutt,et al. Glucose transporter levels in spontaneously obese (db/db) insulin-resistant mice. , 1990, The Journal of clinical investigation.
[124] Y. Shechter. Insulin-Mimetic Effects of Vanadate: Possible Implications for Future Treatment of Diabetes , 1990, Diabetes.
[125] S. Brichard,et al. Long term improvement of glucose homeostasis by vanadate in obese hyperinsulinemic fa/fa rats. , 1989, Endocrinology.
[126] R. Pederson,et al. Long-Term Effects of Vanadyl Treatment on Streptozocin-Induced Diabetes in Rats , 1989, Diabetes.
[127] I. G. Fantus,et al. Pervanadate [peroxide(s) of vanadate] mimics insulin action in rat adipocytes via activation of the insulin receptor tyrosine kinase. , 1989, Biochemistry.
[128] L. Rossetti,et al. Correction of chronic hyperglycemia with vanadate, but not with phlorizin, normalizes in vivo glycogen repletion and in vitro glycogen synthase activity in diabetic skeletal muscle. , 1989, The Journal of clinical investigation.
[129] C. Kahn,et al. Hepatic phosphotyrosine phosphatase activity and its alterations in diabetic rats. , 1989, The Journal of clinical investigation.
[130] P. Vicario,et al. The insulin-mimetic effect of vanadate is not correlated with insulin receptor tyrosine kinase activity nor phosphorylation in mouse diaphragm in vivo. , 1989, Endocrinology.
[131] J. Meyerovitch,et al. Oral administration of vanadate normalizes blood glucose levels in streptozotocin-treated rats. Characterization and mode of action. , 1987, The Journal of biological chemistry.
[132] A. Ullrich,et al. Human insulin receptors mutated at the ATP-binding site lack protein tyrosine kinase activity and fail to mediate postreceptor effects of insulin. , 1987, The Journal of biological chemistry.
[133] J. K. Grady,et al. Vanadium complexes of transferrin and ferritin in the rat. , 1986, Biochimica et biophysica acta.
[134] A. Green. The insulin-like effect of sodium vanadate on adipocyte glucose transport is mediated at a post-insulin-receptor level. , 1986, The Biochemical journal.
[135] W. Mitch,et al. Selectivity of the insulin-like actions of vanadate on glucose and protein metabolism in skeletal muscle. , 1985, The Biochemical journal.
[136] J. McNeill,et al. Effect of vanadate on elevated blood glucose and depressed cardiac performance of diabetic rats. , 1985, Science.
[137] M. Olive,et al. Lipid synthesis in isolated rat hepatocytes: activation by insulin and vanadate and inhibition by ouabain. , 1984, Biochemistry international.
[138] S. Tamura,et al. A novel mechanism for the insulin-like effect of vanadate on glycogen synthase in rat adipocytes. , 1984, The Journal of biological chemistry.
[139] B. R. Nechay. Mechanisms of action of vanadium. , 1984, Annual review of pharmacology and toxicology.
[140] N. Chasteen. The biochemistry of vanadium , 1983 .
[141] G. Swarup,et al. Inhibition of membrane phosphotyrosyl-protein phosphatase activity by vanadate. , 1982, Biochemical and biophysical research communications.
[142] R. C. Nordlie,et al. Vanadate: a potent inhibitor of multifunctional glucose-6-phosphatase. , 1981, Biochimica et biophysica acta.
[143] H. Degani,et al. Electron paramagnetic resonance studies and insulin-like effects of vanadium in rat adipocytes. , 1981, Biochemistry.
[144] T. Clausen,et al. The relationship between the transport of glucose and cations across cell membranes in isolated tissues. XI. The effect of vanadate on 45Ca-efflux and sugar transport in adipose tissue and skeletal muscle. , 1981, Biochimica et biophysica acta.
[145] F. L. Crane,et al. Does vanadium play a role in cellular regulation? , 1981, Current topics in cellular regulation.
[146] G. Dubyak,et al. The insulin-mimetic effects of vanadate in isolated rat adipocytes. Dissociation from effects of vanadate as a (Na+-K+)ATPase inhibitor. , 1980, The Journal of biological chemistry.
[147] F. L. Crane,et al. Vanadate inhibits mevalonate synthesis and activates NADH oxidation in microsomes , 1980, FEBS letters.
[148] Y. Shechter,et al. Insulin-like stimulation of glucose oxidation in rat adipocytes by vanadyl (IV) ions , 1980, Nature.
[149] A. Pansini,et al. Effects of vanadium on glucose metabolism in vitro. , 1979, Life sciences.
[150] A. R. Byrne,et al. Vanadium in foods and in human body fluids and tissues. , 1978, The Science of the total environment.
[151] D. Azarnoff,et al. Effect of cholesterol synthesis inhibition in normocholesteremic young men. , 1959, The Journal of clinical investigation.
[152] D. Azarnoff,et al. SITE OF VANADIUM INHIBITION OF CHOLESTEROL BIOSYNTHESIS , 1957 .